Hopkins' Stem Cell Selection Patents Upheld
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns Hopkins University, Becton Dickinson & Company, and Baxter Healthcare Corp. $7 million in damages for its willful infringement of patents involving stem cell selection technology.
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay JohnsHopkins University, Becton Dickinson & Company, and Baxter HealthcareCorp. $7 million in damages for its willful infringement of patents involvingstem cell selection technology.
The judge also ordered an injunction against CellPro's patent-infringingstem cell selection system (Ceprate Stem Cell Concentration System andCeprate LC34 Laboratory Cell Separation System). This injunction will bedelayed in this country until an alternative system, licensed under thepatents, is approved by the FDA.
Johns Hopkins and its licensees requested the delay to ensure that transplantpatients have uninterrupted access to stem cell selection technology. Baxter'sIsolex 300 Magnetic Cell Separator System, already in widespread use inclinical trials, is currently under FDA review.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
